Home World News Talquetamab Continues To Demonstrate High Overall Response Rates in Heavily Pretreated Patients... World News Talquetamab Continues To Demonstrate High Overall Response Rates in Heavily Pretreated Patients with Relapsed or Refractory Multiple Myeloma By Ogkologos - April 1, 2025 882 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the MonumenTAL-1 study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR First New Drug in Years Reduces Recurrence in High-risk Hormone Receptor... September 20, 2020 FDA Approves Durvalumab for Resectable Gastric or Gastro-Oesophageal Junction Adenocarcinoma December 5, 2025 Adding PD1 Inhibitor to Neoadjuvant Chemotherapy Significantly Increases the pCR Rate... February 12, 2025 NCI’s Rare Cancer Clinics: Engaging Patients and Fostering Collaboration February 28, 2019 Load more HOT NEWS Is there a future without Pap testing? Can Chemotherapy Drugs Be Designed to Avoid Side Effects? Making Cancer Care More Equitable: A Cancer Survivor’s Story Expanding the horizons of the life science economy
